Form 4 for MDGL MADRIGAL PHARMACEUTICALS, INC.
Accepted 2023-01-18 00:00:00 ET · period of report 2023-01-16 · accession 0000899243-23-002095 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-01-18 | 2023-01-16 | MDGL | FRIEDMAN PAUL A | CEO, Dir | A - Grant | $0.00 | +26.7K | 26.7K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-01-16 | A | A | 26,668 | $0.00 | 26,668 | D | — | — | (F1) Represents a grant of restricted stock units, which vest as to 25% of the shares on each of January 13, 2024, January 13, 2025, January 13, 2026 and January 13, 2027, provided the Reporting Person continues in service with the Issuer on each such date. |